Blogs
Healthcare and Medtech Research Reports
Sep 18, 2026
Summary The FDA approved Scholar Rock’s ISEMBYLD on September 11, 2026, the first and only muscle-targeted therapy for SMA, for adults and children aged 2+ who are already on an SMN2-targeted treatment. The FDA approval was based on the Phase 3 SAPPHIRE trial, which enrolled 188 patients aged 2–21 with 5q S...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper